

# **Reducing Recurrent Stroke: Methodology of the Motivational Interviewing in Stroke (MIST) randomised clinical trial**

Rita Krishnamurthi<sup>1</sup>, Emma Witt<sup>1</sup>, Suzanne Barker-Collo<sup>2</sup>, Kathryn McPherson<sup>3</sup>, Kelly Davis-Martin<sup>1,4</sup>, Derrick Bennett<sup>5</sup>, Elaine Rush<sup>6</sup>, Flora Suh<sup>1</sup>, Nicola Starkey<sup>7</sup>, Varsha Parag<sup>8</sup>, Yogini Rathnasabapathy<sup>9</sup>, Amy Jones<sup>1</sup>, Paul Brown<sup>10</sup>, Braden Te Ao<sup>1</sup>, Valery Feigin<sup>1</sup> on behalf of the ARCOS IV Programme Group.

<sup>1</sup>National Institute for Stroke and Applied Neurosciences, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland, New Zealand

<sup>2</sup>Department of Psychology, University of Auckland

<sup>3</sup>Person-Centered Rehabilitation Centre, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland, New Zealand

<sup>4</sup>Harvard Institute of Coaching, Mclean Hospital, Harvard University, Boston, Massachusetts, USA

<sup>5</sup>Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.

<sup>6</sup>Faculty of Health and Environmental Sciences Auckland University of Technology, Auckland, New Zealand

<sup>7</sup>Department of Psychology, Waikato University, Hamilton, New Zealand

<sup>8</sup>National Institute for Health Innovation, University of Auckland, New Zealand

<sup>9</sup>Waitemata District Health Board, North Shore Hospital, Auckland New Zealand

<sup>10</sup>School of Social Sciences, Humanities and Arts, University of California, Merced CA, USA

Corresponding author: Professor Valery L Feigin, MD, MSc, PhD, FAAN

National Institute for Stroke and Applied Neurosciences, Faculty of Health and Environmental Studies, AUT University, , Private Bag 92006, Auckland 1142, New Zealand. Telephone: +64 9 921 9166; Fax: +64 9 921 9620; Email: valery.feigin@aut.ac.nz

*Key words: recurrent stroke, secondary prevention, motivational interviewing, adherence*

## **Abstract**

*Rationale* Recurrent stroke is prevalent in both developed and developing countries, contributing significantly to disability and death. Recurrent stroke rates can be reduced by adequate risk factor management. However, adherence to prescribed medications and lifestyle changes recommended by physicians at discharge after stroke is poor. Motivational Interviewing early after stroke occurrence has the potential to prevent recurrent stroke.

*Aims* The overall aim of the study is to determine the effectiveness of motivational interviewing in improving adherence to medication and lifestyle changes recommended by treating physicians at and after hospital discharge in stroke patients 12 months post-stroke, to reduce risk factors for recurrent stroke.

*Design* Recruitment of 430 first-ever stroke participants will occur in the Auckland and Waikato regions. Randomisation will be to intervention or usual care groups. Participants randomised to intervention will receive four Motivational Interviews and five follow-up assessments over 12 months. Non-intervention participants will be assessed at the same time points.

*Study outcomes* Primary outcome measures are changes in systolic blood pressure and low-density lipoprotein levels 12 months post stroke. Secondary outcomes include self-reported adherence and barriers to prescribed medications.

*Discussion* The results of the MIST trial will add to our understanding of whether Motivational Interviewing may be potentially beneficial in the management of stroke and other diseases where similar lifestyle factors or medication adherence are relevant.

## **Introduction**

Strokes recur in 6-25% of people (1, 2), usually in the first year (1). By 5-years post-stroke, the cumulative risk of recurrent stroke is 30%-40%. Recurrent stroke may lead to greater disability, institutionalisation, increased risk of dementia and a high risk of death (3), and therefore poorer health and economic outcomes (4).

Management strategies for secondary stroke prevention are well established. The landmark INTERSTROKE studies suggest that 10 risk factors are associated with 90% of the risk of first-ever stroke (5). Recurrent strokes are largely preventable using similar strategies to that of primary stroke prevention (6). In a systematic review, lifestyle modifications were shown to be effective for secondary stroke prevention with improvements seen in both lifestyle behaviour changes and physiological outcomes (7). While adherence to prescribed medications and/or recommendations to lifestyle changes after first stroke are effective strategies to reduce recurrent stroke, in practice the implementation of these recommendations is poor (8, 9). Targeting adherence may be key to reducing the incidence of recurrent stroke, therefore it is both appropriate and timely to conduct trials to assess whether new approaches may improve patient adherence to evidence-based guidelines for secondary stroke prevention (10) after hospital discharge.

Motivational Interviewing (MI) is a structured, patient-focused (11, 12) and cost-effective (13) intervention that was originally developed for the treatment of people with problem drinking, addictions (14, 15), stroke (16, 17), traumatic brain injury (18), and cardiovascular disease (19). The objective of MI is to help the client to explore their ambivalence towards behaviour change, and by resolving this ambivalence, facilitating positive behaviour change in the individual (20).

A significant benefit of MI on mood early after stroke over usual stroke care was recently demonstrated in a randomised controlled trial (16). While this intervention has been identified as a high research priority (21), no studies have been carried out specifically to test the effectiveness of

MI in reducing risk factors related to recurrent stroke. Given its potential to encourage patients to adhere to medication and life-style changes recommended by clinicians, this trial is designed to assess the effectiveness of MI in reducing outcomes related to recurrent stroke.

### ***Objectives***

The overall aim of the study is to determine the effectiveness of MI in improving adherence to medication and lifestyle changes recommended by treating physicians at and after hospital discharge in stroke patients 12 months post-randomisation.

### **Methods**

#### ***Trial Design***

This is a phase III single-blind randomised controlled trial of participants with first ever stroke (excluding subarachnoid haemorrhage) followed for 12-months after randomisation. Participants are randomised to either the MI intervention group, (henceforth referred to as MI) or usual care (UC). Recruitment for the trial commenced on 1<sup>st</sup> March 2011 with the population based ARCOS IV Incidence and Outcomes Study (22). Figure 1 ([Appendix 1](#)) is a flowchart of the overall trial design of the MIST study.

## **Patient Population- inclusion and exclusion criteria**

*Inclusion Criteria:* All consecutive adult (16 years or older) stroke survivors who had a first ever stroke and are residents of Auckland or Waikato Region. Stroke is defined according to the World Health Organisation definition as “rapidly developing clinical signs of focal (or global) disturbance of cerebral function, with symptoms lasting 24 hours or longer or leading to death, with no apparent cause other than of vascular origin” (23). A diagnostic review committee comprising four stroke neurologists meet fortnightly to confirm the diagnosis of stroke and classification of all ischaemic cases (22).

*Exclusion criteria:* (1) recurrent stroke (excluding clinically silent previous strokes); (2) a diagnosis of subarachnoid haemorrhage; (3) significant impairments precluding participation (e.g., aphasia); (4) inability to give informed consent; (6) another condition likely to impact their participation in the trial (e.g., life-threatening condition other than cardiovascular disease); (5) expected discharge to hospital/nursing home setting where adherence to lifestyle recommendations and medications is beyond participant control.

## ***Ethical Approval and trial registration***

The study was given ethical approval by the Northern X Regional Ethics Committee for experiments in human subjects and the Auckland University of Technology Ethics Committee. The trial is registered with the Australian New Zealand Clinical Trial Registry (Trial Registration Number: ACTRN 12610000715077).

## ***Recruitment***

Between 1st March 2011 and 29th February 2012, potential participants were recruited for the trial from the main ARCOS IV Incidence and Outcomes study (22). Additional participants were recruited from the Waikato region for the same period. From 1st March 2012, participants will be recruited

from all four Auckland public hospitals and the recruitment period is expected to continue up to December 2013. Daily searches of admissions data are carried out in all four Auckland region public hospitals for records suggestive of a diagnosis of first-ever stroke.

### ***Informed consent***

Potentially eligible participants are identified by a hospital-based research assistant (RA) via regular checks of each hospital database for new admissions and participation at weekly medical and diagnostic team meetings for relevant hospital wards/units. Potential participants are approached by an RA to give informed consent to participate.

### ***Screening***

All participants who meet the main inclusion criteria and provide informed consent undergo a face-to-face detailed screening process with a study RA to ensure that they meet the eligibility criteria for randomisation into the trial. Table 1 ([Appendix 1](#)) shows the eligibility screening criteria used to identify participants eligible for randomisation.

## **Randomisation**

Eligible study participants are randomised to either the MI or UC groups using web-based computerised randomisation software. A stratified minimisation algorithm is used to randomize participants in order to balance possible prognostic factors (i.e., age [ $<70$ ,  $70+$ ], stroke severity [Barthel Index  $<18$  and  $\geq 18$ ], gender and ethnicity [European, non-European]) across the two groups.

Additional information regarding randomisation procedures are in [Appendix 2](#).

## ***Blinding***

To reduce measurement bias, follow-up assessments are carried out by individual community-based RAs who are blind to the treatment allocation of the participant and not involved in the delivery of the intervention. See [Appendix 2](#) for additional information.

## **Motivational Interviewing Intervention**

The trial intervention is based on the principles of MI as described by Miller and Rollnick (24). To assist the interviewers in adhering to a standardised approach and format when conducting the intervention, an intervention manual has been developed providing guidance for each of the intervention time points and appropriate tools to assist in the interviewing process.

MI interviews are conducted at 28 days, 3, 6 and 9 months post stroke (see flowchart Figure 1 [Appendix 1](#)). Further details of the trial intervention are in [Appendix 2](#).

## **Primary Outcomes**

Primary outcome measures are (1) change in systolic blood pressure (SBP) and (2) low-density lipoprotein (LDL)-cholesterol levels at 12 months post stroke.

## Secondary Outcomes

Secondary outcome measures are: (a) self-reported adherence to prescribed medications, including self-reported use of anti-platelet/anticoagulant medications, statin and blood pressure lowering therapy medications as prescribed (and cross-checked with electronic medication dispense records, where available); (b) self-reported barriers to adherence to medications; (c) cardiovascular events (new stroke or coronary heart disease, both fatal and non-fatal); (d) quality of life as measured by the SF-36 (25); (e) mood as measured by the Hospital Anxiety and Depression Scale (HADS) (26); (f) change in other blood lipid levels (HDL-cholesterol, total cholesterol, and triglycerides); (g) physical disability as measured by the Barthel Index (27) at 12 month and; (h) healthcare resource consumption and cost-effectiveness of the intervention.

Outcome assessments (Table 2, [Appendix 1](#)) are carried out at 28 days, 3, 6, 9 and 12 months following stroke.

### ***Withdrawals and Loss to follow-up***

Participants are able to withdraw their involvement in the study at any time. The “intention-to-treat” principle will apply for participants who withdraw from the study or are lost to follow-up, so that data from up to and including their last completed assessment will be included in the analyses.

### ***Data Management***

Data management services including statistical analyses are contracted to the National Institute for Health Innovation (NIHI), The University of Auckland. For further details see [Appendix 2](#).

### **Data Safety Monitoring**

[See Appendix 2](#)

### **Sample size**

Four hundred and thirty participants are required to provide 85% power at  $\alpha=0.05$  (two-sided) to detect a 0.25 mmol/l difference in LDL-cholesterol (SD 0.8 mmol/L), and 80% power to detect a 4 mmHg difference in SBP (SD 14 mmHg), respectively, between UC and MI groups, assuming 10% loss to follow-up.

### **Statistical analyses**

All statistical analyses will be performed using SAS version 9.3 (SAS Institute Inc. Cary NC). All tests of significance will be two-tailed and at 5% significance level throughout the analyses. Further details are available in [Appendix 2](#).

### ***Cost effectiveness***

The cost effectiveness of the study will be determined by comparing the costs and outcomes associated with the control group with the group provided with MI. For additional information see [Appendix 2](#).

### **Study organisation and funding**

The study is hosted at the National Institute for Stroke and Applied Neurosciences at AUT University, Auckland New Zealand. The research is funded by the Health Research Council of New Zealand.

### **Summary**

The MIST study is a randomised clinical trial designed to test the effectiveness of MI for the secondary prevention of stroke. To the best of our knowledge, this is one of the largest clinical trials of MI to be carried out at a population level. This intervention has the potential benefits of being adapted in the community as a cost-effective means of reducing stroke burden. In addressing the values and goals of individuals after stroke, MI may present a multifactorial approach to concomitant reduction of risk factors.

### **Acknowledgements**

The authors wish to acknowledge the contribution of the trial participants, the ARCOS IV and MIST study research assistants, medical staff at all the Auckland and Waikato DHBs.

MIST Data Safety Monitoring Committee and ARCOS IV Steering Committee, see [Appendix 2](#).

## References

1. Talelli P, Greenwood RJ, Talelli P, Greenwood RJ. Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes? *Therapeutic Advances in Cardiovascular Disease*. [Review]. 2008 Oct;2(5):387-405.
2. Hankey GJ, Hankey GJ. Secondary prevention of recurrent stroke. *Stroke*. [Review]. 2005 Feb;36(2):218-21.
3. Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. *Stroke*. 2004;35(3):731-5.
4. Phillips RA, Phillips RA. A review of therapeutic strategies for risk reduction of recurrent stroke. *Progress in Cardiovascular Diseases*. [Research Support, Non-U.S. Gov't Review]. 2008 Jan-Feb;50(4):264-73.
5. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. *Lancet*. [Multicenter Study Research Support, Non-U.S. Gov't]. 2010 Jul 10;376(9735):112-23.
6. Wolf PA, Clagett GP, Easton JD, Goldstein LB, Gorelick PB, Kelly H, et al. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack : a statement for healthcare professionals from the stroke council of the American Heart Association. *Stroke*. 1999 09;30(9):1991-4.
7. Lawrence M, Kerr S, McVey C, Godwin J. The effectiveness of secondary prevention lifestyle interventions designed to change lifestyle behavior following stroke: summary of a systematic review. *International Journal of Stroke*. [Research Support, Non-U.S. Gov't Review]. 2012 Apr;7(3):243-7.
8. Brown MT, Bussell JK. Medication adherence: WHO cares? *Mayo Clinic Proceedings*. 2011;86(4):304-14.
9. Sabaté E., editor. *Adherence to Long-Term Therapies: Evidence for Action*. Geneva, Switzerland 2003.
10. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. *Circulation*. [Practice Guideline]. 2006 Mar 14;113(10):e409-49.
11. Miller RW, Rollnick S. *Motivational interviewing: Preparing people to change addictive behavior*. New York, NY: The Guilford Press; 1991.
12. Rollnick S, Mason P, Butler C. *Health behavior change: a guide for practitioners*. New York, NY: Churchill Livingstone; 2000.

13. Heather N. Motivational interviewing: Effectiveness and cost-effectiveness. *Addiction*. 2001;96(12):1772-3.
14. Stein LAR, Lebeau R, Colby SM, Barnett NP, Golembeske C, Monti PM. Motivational interviewing for incarcerated adolescents: effects of depressive symptoms on reducing alcohol and marijuana use after release. *J Stud Alcohol*. [Comparative Study Randomized Controlled Trial Research Support, N.I.H., Extramural]. 2011 May;72(3):497-506.
15. Smith AJ, Shepherd JP, Hodgson RJ. Brief interventions for patients with alcohol-related trauma. *Br J Oral Maxillofac Surg*. [Research Support, Non-U.S. Gov't Review]. 1998 Dec;36(6):408-15.
16. Watkins CL, Auton MF, Deans CF, Dickinson HA, Jack CI, Lightbody CE, et al. Motivational interviewing early after acute stroke: a randomized, controlled trial. *Stroke*. [Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 2007 Mar;38(3):1004-9.
17. Leathley MJ, Fall S, Sharma AK, Watkins C, Barer D. Life after stroke: multi-centre trial of psychosocial interventions after stroke. *Cerebrovascular Disease*. 2003;16 (suppl 4):70.
18. Bombardier CH, Bell KR, Temkin NR, Fann JR, Hoffman J, Dikmen S, et al. The efficacy of a scheduled telephone intervention for ameliorating depressive symptoms during the first year after traumatic brain injury. *Journal of Head Trauma Rehabilitation*. [Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 2009 Jul-Aug;24(4):230-8.
19. Woollard J, Beilin L, Lord T, Puddey I, MacAdam D, Rouse I. A controlled trial of nurse counselling on lifestyle change for hypertensives treated in general practice: preliminary results. *Clinical & Experimental Pharmacology & Physiology*. [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 1995 Jun-Jul;22(6-7):466-8.
20. Miller WR, Rollnick S. *Motivational Interviewing: Preparing People for Change*. 2nd ed. New York: Guilford Press; 2002.
21. Longabaugh R. Comments on Dunn et al.'s "The use of brief interventions adapted from motivational interviews across behavioral domains: a systematic review". Why is motivational interviewing effective? *Addiction*. [Comment]. 2001 Dec;96(12):1773-4; discussion 4-5.
22. Krishnamurthi R., Jones A., Barber A., Barker-Collo S., McPherson K., Bennett D., et al. Methodology of a Population-Based Stroke and TIA Incidence and Outcomes Study: The Auckland Regional Community Stroke Study (ARCOS IV) 2011-2012. *International Journal of Stroke*. 2013.
23. Aho K, Harmsen P, Hatano S, Marquardsen J, Smirnov VE, Strasser T. Cerebrovascular disease in the community: results of a WHO collaborative study. *Bulletin of the World Health Organization*. 1980;58(1):113-30.
24. Miller RW, Rollnick S. *Motivational interviewing: preparing people to change addictive behavior*. New York, NY: The Guilford Press; 1991.
25. Ware JE, Kosinski M, Keller SD. *SF-36 Physical and Mental Health Summary Scales: A Users Manual*. Boston, Mass: The Health Institute, New England Medical Centre; 1994.
26. Johnston M, Pollard B, Hennessey P. Construct validation of the hospital anxiety and depression scale with clinical populations. *Journal of Psychosomatic Research*. 2000;48(6):579-84.

27. Sulter G, Steen C, De KJ. Use of the Barthel index and modified Rankin scale in acute stroke trials. *Stroke*. 1999 08;30(8):1538-41.

